An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in 
ovarian cancer cells

Sheng, Qing; Liu, Xinggang; Fleming, Eleanor; Yuan, Karen; Chen, Jinyun; Moustafa, Zeinab; Thomas, Roman K.; Greulich, Heidi; Schinzel, Anna C.; Zaghlul, Sara; Batt, David; Ettenberg, Seth; Meyerson, Matthew; Schoeberl, Birgit; Kung, Andrew L.; Hahn, William C.; Drapkin, Ronny; Livingston, David M.; Liu, Joyce

doi:10.1016/j.ccr.2009.12.047

Datensatz

DATENSATZ AKTIONENEXPORT

Zur Ablage hinzufügen

Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben

Zeitschriftenartikel

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells

MPG-Autoren

Sheng, Qing
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Liu, Xinggang
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Fleming, Eleanor
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Yuan, Karen
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Chen, Jinyun
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Moustafa, Zeinab
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

/persons/resource/persons147315

Thomas, Roman K.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Greulich, Heidi
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Schinzel, Anna C.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Zaghlul, Sara
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Batt, David
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Ettenberg, Seth
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Meyerson, Matthew
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Schoeberl, Birgit
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Kung, Andrew L.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Hahn, William C.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Drapkin, Ronny
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Livingston, David M.
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Liu, Joyce
a Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02115, United States b Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States c Harvard Medical School, Boston, MA 02115, United States d Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, United States e Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States f Novartis Oncology, Cambridge, MA 02139, United States g Department I of Internal Medicine, Center of Integrated Oncology, University of Köln, D-50937 Köln, Germany h Chemical Genomics Center, the Max Planck Society, D-44227 Dortmund, Germany i Broad Institute, Harvard University, the Massachusetts Institute of Technology, Cambridge, MA 02142, United States j Merrimack Pharmaceuticals, Cambridge, MA 02139, United States k Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital, Boston, MA 02115, United States;

Externe Ressourcen

Es sind keine externen Ressourcen hinterlegt

Volltexte (beschränkter Zugriff)

Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.

Volltexte (frei zugänglich)

Es sind keine frei zugänglichen Volltexte in PuRe verfügbar

Ergänzendes Material (frei zugänglich)

Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar

Zitation

Sheng, Q., Liu, X., Fleming, E., Yuan, K., Chen, J., Moustafa, Z., et al. (2010). An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell, 17(10), 298-310. doi:10.1016/j.ccr.2009.12.047.

Zitierlink: https://hdl.handle.net/11858/00-001M-0000-0026-D22F-D